

Instructions For Use

RA0491-C-IFU-RUO

Rev. Date: June, 22nd, 2017

Revision: 1

Page 1 of 2

P.O. Box 3286 - Logan, Utah 84323, U.S.A. - Tel. (800) 729-8350 - Tel. (435) 755-9848 - Fax (435) 755-0015 - www.scytek.com

Carcinoembryonic Antigen, pan (CEA) / CD66; Clone Cocktail (Concentrate)

Availability/Contents: <u>Item #</u> <u>Volume</u>

RA0491-C.1 0.1 ml RA0491-C.5 0.5 ml RA0491-C1 1 ml

Description:

Species: Mouse

Immunogen: Recombinant full-length human CEA protein (C66/195; C66/261; C66/1009 & C66/1030)

Clone: C66/195 & C66/1009 & C66/1030

Isotype: IgGs Entrez Gene ID: 1048; 634

Hu Chromosome Loc.: 19q13.1-19q13.2

Synonyms: Carcinoembryonic Antigen-related Cell Adhesion Molecule 5, CEACAM5, CD66, Biliary

Glycoprotein (BGP-1)

Mol. Weight of Antigen: 80-200kDa

Format: 200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS

with 0.05% BSA & 0.05% azide.

Specificity: This antibody recognizes proteins of 80-200kDa, identified as different members of CEA family.

This MAb does not react with nonspecific cross-reacting antigen (NCA) and with human polymorphonuclear leucocytes. It shows no reaction with a variety of normal tissues and is

suitable for staining of formalin/paraffin tissues.

Background: CEA is synthesized during development in the fetal gut and is re-expressed in increased

amounts in intestinal carcinomas and several other tumors. CEA is not found in benign glands, stroma, or malignant prostatic cells. Antibody to CEA is useful in detecting early foci of gastric carcinoma and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+). Anti-CEA positivity is seen in adenocarcinomas from the lung, colon, stomach, esophagus, pancreas, gallbadder, urachus, salivary gland, ovary, and

endocervix.

Species Reactivity: Human. Others not known.

Positive Control: MCF7 or 293T cells. Colon carcinoma. Cellular Localization: Cytoplasmic and luminal surface.

Titer/ Working Dilution: Immunohistochemistry (Frozen and Formalin-fixed): 0.5-1 µg/ml

Flow Cytometry: 0.5-1 µg/million cells

Microbiological State: This product is not sterile.

Storage: 2° C 8° C

ScyTek Laboratories, Inc. 205 South 600 West Logan, UT 84321 U.S.A.

 ϵ

Emergo Europe
Prinsessegracht 20
2514 AP The Hague, The Netherlands



Instructions For Use RA0491-C-IFU-RUO

Rev. Date: June, 22nd, 2017

Revision: 1

Page 2 of 2

P.O. Box 3286 - Logan, Utah 84323, U.S.A. - Tel. (800) 729-8350 - Tel. (435) 755-9848 - Fax (435) 755-0015 - www.scytek.com

Uses/Limitations: Not to be taken internally.

For Research Use Only.


This product is intended for qualitative immunohistochemistry with normal and neoplastic formalin-fixed, paraffin-embedded

tissue sections, to be viewed by light

microscopy.

Do not use if reagent becomes cloudy. Do not use past expiration date.

Non-Sterile.



Formalin-fixed, paraffin embedded human Colon Carcinoma stained with CEA; Clones C66/195 & C66/1009 & C66/1030.

Ordering Information and Current Pricing at www.scytek.com

Procedure:

- 1. **Tissue Section Pretreatment (Required):** Staining of formalin fixed, paraffin embedded tissue sections is significantly enhanced by pretreatment with Citrate Plus (ScyTek catalog# CPL500).
- Primary Antibody Incubation Time: We suggest an incubation period of 30 minutes at room temperature.
 However, depending upon the fixation conditions and the staining system employed, optimal incubation should be determined by the user.
- 3. **Visualization:** For maximum staining intensity we recommend the "CRF Anti-Polyvalent HRP Polymer (DAB) Lab Pack" (ScyTek catalog# CPP125, see IFU for instructions).

Precautions: Contains Sodium Azide as a preservative (0.09% w/v).

Do not pipette by mouth.

Avoid contact of reagents and specimens with skin and mucous membranes.

Avoid microbial contamination of reagents or increased nonspecific staining may occur.

This product contains no hazardous material at a reportable concentration according to U.S. 29 CFR 1910.1200,

OSHA Hazardous Communication Standard and EC Directive 91/155/EC.

References:

- 1. Muraro R, et. al. Cancer Research, 1985, 45:5769-80.
- 2. Siler K, et. al. Biotechnology Therapeutics, 1993, 4(3-4):163-81.
- 3. Robbins PF, et. al. International Journal of Cancer, 1993, 53(6):892-7.
- 4. Shi ZR, et. al. Journal of Histochemistry and Cytochemistry, 1994, 42(9):1215-9.

Warranty:

No products or "Instructions For Use (IFU)" are to be construed as a recommendation for use in violation of any patents. We make no representations, warranties or assurances as to the accuracy or completeness of information provided on our IFU or website. Our warranty is limited to the actual price paid for the product. ScyTek Laboratories, Inc. is not liable for any property damage, personal injury, time or effort or economic loss caused by our products. Immunohistochemistry is a complex technique involving both histological and immunological detection methods. Tissue processing and handling prior to immunostaining can cause inconsistent results. Variations in fixation and embedding or the inherent nature of the tissue specimen may cause variations in results. Endogenous peroxidase activity or pseudoperoxidase activity in erythrocytes and endogenous biotin may cause non-specific staining depending on detection system used.

Storage: 2° C 8° C

ScyTek Laboratories, Inc. 205 South 600 West Logan, UT 84321 U.S.A. (

Emergo Europe Prinsessegracht 20 2514 AP The Hague, The Netherlands